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Strap muscle invasion 
in differentiated thyroid cancer 
does not impact disease‑specific 
survival: a population‑based study
Ja Kyung Yoon1, Jandee Lee2, Eun‑Kyung Kim1, Jung Hyun Yoon1, Vivian Youngjean Park1, 
Kyunghwa Han1,3* & Jin Young Kwak1*
The American Joint Committee on Cancer (AJCC)  8th TNM staging system of differentiated thyroid 
cancer defines gross strap muscle invasion as T3b stage. However, the impact of strap muscle invasion 
on disease‑specific survival (DSS) remains controversial. To elucidate the survival impact of strap 
muscle invasion of any degree in thyroid cancers, the Surveillance, Epidemiology, and End Results 
(SEER) database (1973–2018) was queried for thyroid cancer only patients on July 2019 (n = 19,914). 
The Cox proportional hazard analysis with multivariable adjustment revealed that strap muscle 
invasion was not a significant factor for DSS in tumors equal to or smaller than 40 mm (hazard 
ratio (HR) = 1.620 [confidence interval (CI) 0.917 – 2.860]; p = 0.097). The competing risk analysis 
with multivariable adjustment showed that strap muscle invasion did not significantly impact DSS 
regardless of tumor size or cause of death (cancer‑caused death (Subdistribution HR (SDHR) = 1.567 
[CI 0.984 – 2.495]; p = 0.059); deaths to other causes (SDHR = 1.155 [CI 0.842 – 1.585]; p = 0.370). A 
“modified” staging schema discarding strap muscle invasion as a T stage criterion showed better 
10‑year DSS distinction between T stages. The modified staging schema may better reflect cancer‑
caused death risk and may prevent potential overstaging.
Extrathyroidal extension (ETE) is defined as the direct extension of the primary thyroid cancer into the adja-
cent structures, including strap muscles, trachea, larynx, esophagus, recurrent laryngeal nerve and/or major 
 vasculature1,2. While strap muscle invasion was subclassified as minimal or gross, the American Joint Committee 
on Cancer (AJCC) 8th edition TNM staging schema discarded the minimal ETE category entirely while defining 
gross strap muscle invasion alone as the T3b stage. Validation studies have corroborated the new staging system 
by showing better allocation of relatively low-risk patients into lower stages with excellent survival  outcomes3, 
and high-risk patients into more advanced  stages3–7.
The newly introduced staging factor of gross strap muscle invasion alone (T3b) has been associated with 
higher risk of positive resection margin, bigger tumor size, higher recurrence rate, and lower disease survival 
 rate8–10. However, studies have reported that strap muscle invasion alone, both minimal and gross, may not have 
significant influence on overall  survival11,12, particularly in tumors equal to or smaller than 40 mm13. A recent 
study has also suggested similar disease-free survival rate between the minimal ETE and gross strap muscle 
invasion alone groups in papillary thyroid carcinomas with tumor size 10- to 40-mm14. With advances in surgi-
cal techniques and adjuvant  therapies13, it is possible that tumors with strap muscle invasion alone may indeed 
have better prognosis than previously anticipated. Therefore, the impact of strap muscle invasion alone, both 
minimal and gross, on the survival of thyroid cancer patients needs to be elucidated to accurately allocate patients 
into appropriate staging groups according to individual risk, which will ensure longer disease-free survival and 
prevent overtreatment.
The Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute (NCI) 
collects cancer incidence and survival information from population-based cancer registries encompassing nearly 
34.6% of the total population of the United  States15. The SEER program is regarded as a critical database for 
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cancer survival surveillance in the United States. This openly available database has compiled cancer incidence 
and survival data since 1973. Accordingly, it is an ideal database for analyzing the effect of gross ETE on overall 
survival in thyroid cancer.
Therefore, the purpose of this study was to explore the impact of strap muscle invasion alone, both minimal 
and gross, on the disease-specific survival (DSS) of differentiated thyroid cancer (DTC) patients using the SEER 
database, and to potentially improve the survival prediction power of the TNM staging schema.
Results
Baseline characteristics. Baseline patient demographics are presented in Table 1. The median age at diag-
nosis was 47.0  years old (interquartile range, 36.0–57.0  years old), with a median follow-up of 55.0  months 
(interquartile range, 32.0–85.0 months; range, 1.0–155.0 months). A total of 18,085 (90.8%) patients were diag-
nosed with papillary carcinoma and its variants, while 1406 (7.1%) patients were diagnosed with follicular carci-
noma and its variants. Other pathologies included oxyphilic adenocarcinoma (n = 355), non-encapsulated scle-
rosing carcinoma (n = 64), and clear cell adenocarcinoma (n = 4). Most patients underwent total thyroidectomy 
(n = 16,874, 84.7%). Adjuvant radiation therapy was performed in over half of the patients (n = 10,165, 51.0%), 
which included radioactive iodine (RAI) (n = 9740), radioactive implants (n = 120), beam radiation (n = 195), a 
combination of beam radiation with implants or isotopes (n = 66), and radiation therapy not otherwise specified 
(n = 44). Adjuvant chemotherapy was performed in only 57 (0.3%) patients. The distribution of T stage accord-
ing to the AJCC 8th staging criteria is shown in Table 2.
Prognostic impact of strap muscle invasion alone on 10‑year DSS. Cox proportional hazard anal-
ysis was performed to estimate the prognostic impact of strap muscle invasion on DSS in all patients (n = 19,914) 
and in the subgroup of patients with tumor size equal to or smaller than 40 mm (n = 17,837) (Table 3). Univari-
able and multivariable analyses revealed that strap muscle invasion alone as well as age, tumor size, major organ 
invasion, major vessel invasion, LN metastasis, distant metastasis, and chemotherapy were significant prognostic 
factors for DSS. Subgroup analysis of tumors equal to or smaller than 40 mm in size showed that although strap 
muscle invasion alone was a significant prognostic factor for DSS on univariable Cox regression analysis, it was 
not a significant prognostic factor for DSS on multivariable analysis.
Table 1.  Baseline patient demographics. Data are presented as numbers (%) unless indicated otherwise. ICD-
O-3 International Classification of Diseases for Oncology, LN lymph node. a Data are shown as medians (1st 
quartile, 3rd quartile).
Patient characteristics Value
Age at diagnosisa 47 (36.0, 57.0)
< 55 years old 13,688 (68.7)








Tumor size (mm)a 15 (8.0, 26.0)
Pathology according to ICD-O-3
Papillary carcinoma 18,085 (90.8)




No or minimal invasion 17,703 (88.9)
Strap muscle invasion alone 1552 (7.8)
Major organ invasion 464 (2.3)
Major vessel invasion 195 (1.0)
LN metastasis 4897 (24.6)
Distant metastasis 229 (1.1)
Total thyroidectomy 16,874 (84.7)
Radiation therapy 10,165 (51.0)
Chemotherapy 57 (0.3)
Follow-up  monthsa 55 (32.0, 85.0)
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Competing risk analysis of cancer‑caused deaths and deaths to other causes. On multivariable 
competing risk analysis, strap muscle invasion alone did not significantly impact death due to either cancer 
or other causes in all patients as well as in the subgroup of tumors equal to or smaller than 40 mm (Table 4), 
although it was a significant factor on univariable analysis (Supplementary Table S1). In addition, in the sub-
group of patients 55 years old of age or older, multivariable competing risk analysis showed that strap muscle 
invasion only did not significantly impact death due to any cause, despite its significance on univariable compet-
ing risk analysis (Supplementary Table S2).
10‑year DSS according to the T stages of the AJCC 8th TNM staging and the modified TNM 
staging schemas. Table 2 showed the 10-year DSS and the number of patients in each T stage according 
to either the AJCC 8th TNM staging schema or the “modified” TNM staging schema (discarding strap muscle 
invasion from the T stage criteria). While there was an overall negative correlation between T stage and 10-year 
DSS per the AJCC 8th staging schema, the T3b stage showed better 10-year DSS than the T3a stage (Fig. 1a). 
Restaging of the T3b stage (i.e.,  T3bNanyMany) according to the modified TNM staging schema resulted in a total 
of 1552 patients assigned to T1a (n = 238, 15.3%), T1b (n = 543, 35.0%), T2 (n = 506, 32.6%), and T3 (n = 265, 
17.1%) stages with significant difference in DSS (Fig. 1b). Among the 1518 patients without distant metastasis 
(i.e.,  T3bNanyM0, stage II), 589 patients (38.8%) were downstaged to stage I, and there was significant difference 
in DSS after reallocation into either stage I or stage II (Fig. 1c,d). T stage and overall staging reallocation per the 
modified staging schema is shown in Fig. 2.
Evaluation of the power of survival prediction for the AJCC 8th and the modified TNM stag‑
ing schemas. The Harrell’s C concordance indices (C-indices) of the AJCC 8th and the modified TNM 
staging schemas was estimated as 0.9418 and 0.9405, respectively, but without statistically significant difference 
(p = 0.220). The proportion of variance explained (PVE) for DSS prediction with the AJCC 8th and the modified 
TNM staging schemas was estimated as 4.45% and 4.43%, respectively.
Discussion
This study suggested that strap muscle invasion alone of any degree was not a statistically significant prognostic 
factor of DSS in all tumor sizes of DTC. In particular, this finding may significantly impact tumors equal to 
or smaller than 40 mm, which may be overstaged by the current AJCC 8th TNM staging schema. In addition, 
survival analysis of the T3b group according to the AJCC 8th TNM staging schema showed that it consists of a 
heterogeneous group of patients with significantly different DSS according to tumor size. T3b patients reallocated 
to either the T1 or T2 stage according to the suggested modified staging schema showed significantly better DSS 
compared to those in the T3 stage.
Historically, ETE was assumed to have a positive correlation with compromised survival in  DTC16,17, but with 
some  controversy18,19. While minimal ETE was totally discarded from the AJCC 8th TNM staging schema, gross 
strap muscle invasion was introduced as the new T3b stage regardless of tumor size. However, there have been 
suggestions that even gross strap muscle invasion does not impact survival in patients with  DTC8–11,13,20. Indeed, 
the AJCC 8th staging schema contains in-stage heterogeneity in regards to DSS  prediction21. One potential source 
of this heterogeneity may be due to the prognostic impact of strap muscle invasion. A recent study of a total 
Table 2.  10-year DSS and T stage distribution according to the AJCC 8th TNM staging schema or modified 
TNM staging schema (n = 19,914). Statistically significant values are shown in bold. DSS disease-specific 
survival, HR hazard ratio, CI confidence interval. a Staging according to the American Joint Committee on 
Cancer (AJCC) 8th edition of TNM classification. b Staging according to the suggested modified TNM staging 
schema discarding the strap muscle invasion factor from the T staging criteria.
n (%) 10-year DSS (%) HR 95% CI p value
AJCC TNM8a < 0.001
T1a 6610 (33.2) 99.4 1 Reference
T1b 5258 (26.4) 99.4 2.008 0.920–4.386 0.080
T2 4249 (21.3) 98.0 5.381 2.676–10.821 < 0.001
T3a 1586 (8.0) 93.1 19.144 9.685–37.839 < 0.001
T3b 1552 (7.8) 96.4 13.177 6.442–26.955 < 0.001
T4a 464 (2.3) 86.2 65.291 32.946–129.388 < 0.001
T4b 195 (1.0) 70.0 146.927 74.023–291.632 < 0.001
Modified TNMb < 0.001
T1a 6848 (34.4) 99.4 1.000 Reference
T1b 5801 (29.1) 99.3 1.900 0.957–3.772 0.067
T2 4755 (23.9) 97.8 4.810 2.599–8.904 < 0.001
T3 1851 (9.3) 92.6 16.802 9.232–30.579 < 0.001
T4a 464 (2.3) 86.2 52.082 28.137–96.408 < 0.001
T4b 195 (1.0) 70.0 117.249 63.230–217.418 < 0.001
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of 2804 patients and demonstrated that perithyroidal soft tissue or strap muscle invasion showed disease-free 
survival, overall survival and DSS comparable to those of intrathyroidal tumors equal to or smaller than 40 mm 
(median follow-up 59 months; range, 12–192 months), although with small number of strap muscle invasion 
cases (n = 61)13. Another study on 3104 patients with either papillary or follicular thyroid carcinoma revealed 
that gross strap muscle invasion does not significantly impact DSS in tumors equal to or smaller than 40 mm, 
and that DSS of the T3b stage did not significantly differ from that of the T2 stage (median follow-up 10 years; 
interquartile range, 8.1–12 years)11.
This population-based study utilized the SEER  database15 without discrimination of tumor size to reveal 
that strap muscle invasion alone does not significantly impact DSS, regardless of tumor size or cause of death. 
This may have particular clinical impact on tumors equal to or smaller than 40 mm which may be appropriately 
downstaged. Although the estimated C-indices and PVE did not reveal statistically significant differences in the 
predictive power of the current AJCC 8th and the suggested modified TNM staging schemas, better survival 
curve separation was observed per the modified staging schema with statistical significance.
Invasion of strap muscle in any degree may not have significant survival impact due to the relative complexity 
of posterior anatomical structures such as trachea, recurrent laryngeal nerve, and prevertebral fascia. Critical 
laryngotracheal structure invasion leads to a higher possibility of incomplete resection and therefore to higher 
clinical recurrence and poorer  prognosis9. On the other hand, strap muscles can be relatively easily resected in 
the presence of tumor  invasion13,22, accounting for their lack of significant impact on DSS. Consequently, anterior 
or posterior ETE have been suggested as more appropriate staging factors than gross strap muscle  invasion13,23. 
Therefore, the dismissal of both minimal and gross strap muscle invasion may lead to better allocation by the 
Table 3.  Cox proportional hazard analysis for disease-specific survival (DSS) according to the AJCC 8th TNM 
staging schema. Statistically significant values are shown in bold. DSS disease-specific survival, HR hazards 
ratio, CI confidence interval, ETE extrathyroidal extension, LN lymph node.
Variables
All patients (n = 19,914) Tumor size ≤ 40 mm (n = 17,837)
Univariable Multivariable Univariable Multivariable
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
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TNM staging schema and better reflection of DSS, as suggested by the modified staging schema, particularly for 
tumors equal to or smaller than 40 mm.
There are several limitations to our study. First, the retrospective nature of this study may have caused an 
inherent bias. Second, the SEER database did not distinguish between minimal and gross strap muscle invasion. 
However, any ETE beyond strap muscle invasion was explicitly recorded and an inference was made that the 
code for strap muscle invasion included both minimal and gross strap muscle invasion collectively. Thus, the 
purpose of this study was limited to exploring the potential changes in TNM staging with the collective dismissal 
of both minimal and gross strap muscle invasions. Third, the SEER database did not include recurrence data, 
which limited the analysis of the impact of strap muscle invasion alone on disease-free survival. Strengths of the 
present study include the use of a national, comprehensive database with analyses of prognostic variables in all 
tumor size groups as well as tumor size and age subgroups. Moreover, competing risk analysis offered a more 
accurate evaluation of potential prognostic variables relative to other causes of death.
In conclusion, strap muscle invasion alone of any degree does not significantly impact DSS in DTC patients, 
regardless of tumor size. The modified TNM staging schema suggests potential modification of the TNM staging 
schema to better reflect the risk of cancer-caused death and to prevent potential overstaging of tumors, particu-
larly those equal to or smaller than 40 mm in size.
Methods
SEER database and study population. The SEER database was accessed on July 4th, 2019, and queried 
for all patients diagnosed with DTC alone. Inclusion criteria were as follows: (1) patients older than 18 years 
old, (2) patients diagnosed with only DTC according to the International Classification of Disease for Oncol-
ogy, third edition (ICD-O-3) codes (Supplementary Table S3), and (3) patients who underwent surgery with or 
without adjuvant radiation therapy or chemotherapy. Patients with medullary carcinoma, mixed medullary car-
cinoma component, insular carcinoma, and anaplastic thyroid cancer were excluded. In addition, patients with 
unknown race, unknown tumor grade, unknown ETE, unavailable or incomplete TNM staging data, death cer-
tificate or autopsy alone, or unknown cause of death were excluded (Fig. 3). The extension item of the SEER Can-
cer Schema (CS) version 02.05.50, which encodes tumor ETE based on pathologic and/or clinical information, 
does not explicitly distinguish between minimal or gross strap muscle invasion. However, since more advanced 
Table 4.  Multivariable competing risk analysis of clinical and pathological variables for cancer–caused 
death according to the AJCC 8th TNM staging schema. Statistically significant values are shown in bold. DSS 
disease-specific survival, SDHR subdistribution hazards ratio, CI confidence interval, ETE extrathyroidal 
extension, LN lymph node.
Variables
All (n = 19,914) Tumor size ≤ 40 mm (n = 17,837)
Cancer–caused death 
(n = 233)




Death to other causes 
(n = 305)
SDHR (95% CI) p value SDHR (95% CI) p value SDHR (95% CI) p value SDHR (95% CI) p value
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organ invasion (i.e., recurrent laryngeal nerve, vagus nerve, major vessels, major organs or prevertebral fascia) 
was clearly distinguished by the CS extension coding, the invasion of omohyoid, sternohyoid, sternothyroid and/
or thyrohyoid muscles (code 450) was considered to include both minimal and gross strap muscle invasion col-
lectively. This code was regarded as the T3b stage per the AJCC 8th TNM staging schema in this study.
A total of 19,914 patients were included in the final analysis of demographic variables including age at 
diagnosis, race, sex, year of diagnosis and survival status. Pathologic characteristics included single or multifo-
cal disease, tumor size, ETE, LN metastasis and distant metastasis. This retrospective study utilizing a publicly 
available database with de-identified records did not require informed consent from the SEER registered cases, 
and Institutional Review Board approval was formally waived.
Primary outcome. The primary outcome of this study was cancer-caused death from DTC. DSS was 
defined as the time from date of diagnosis until cancer-caused death or last censoring.
Tumor staging. Because the currently available SEER database only provides TNM staging according to 
the AJCC 7th or previous staging schemas, the included 19,914 patients were restaged according to the AJCC 
8th TNM staging schema using the recorded pathologic characteristics. Strap muscle invasion alone (code 450 
of the CS extension item in the SEER CS version 02.05.50) was categorized as T3b stage, while pericapsular soft 
tissue or connective tissue invasion was categorized according to tumor size only. Major organ invasion includ-
ing gross invasion of the subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve from 
Figure 1.  Comparison of DSS of the T3b subgroup according to the AJCC 8th TNM staging and modified 
TNM staging schemas and alluvial plot of restaging according to the two staging schemas. (a,b) Comparison 
of the disease-specific survival (DSS) between the T3a and T3b stages according to the AJCC 8th TNM staging 
schema (a) and the modified TNM staging schema (b). Reallocation of the T3a and T3b stages according to the 
modified TNM staging schema (b) showed significantly different DSS according to tumor size only (p < 0.001). 
(c,d) Comparison of DSS of the  T3bNanyM0 group according to the AJCC 8th TNM staging schema (c) and the 
modified TNM staging schema (d). The  T3bNanyM0 group (c) was classified as stage II with the AJCC 8th TNM 
staging schema. According to the modified TNM staging schema (d), the  T3bNanyM0 group was reallocated to 
either stage I or stage II with statistically significant difference in DSS (p = 0.015).
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any tumor size was classified as T4a stage per the AJCC 8th TNM staging schema. Likewise, major vessel and/or 
prevertebral fascia invasions including the encasement of carotid artery or mediastinal vessels from any tumor 
size were classified as T4b stage.
Based on our hypothesis that minimal and gross strap muscle invasion collectively in the absence of other 
risk factors does not significantly impact DSS, we suggested a “modified” staging schema thereby discarding 
strap muscle invasion of any degree from the T staging criteria. Therefore, T3b stage according to the AJCC 8th 
TNM staging schema were reallocated depending on tumor size only, into either the T1a, T1b, T2, or T3 stage 
per the modified staging schema. The staging of major adjacent structures extension (i.e., T4a or T4b stages) 
remained unchanged.
Figure 2.  Restaging of the AJCC 8th TNM stages according to the modified TNM staging schema. The alluvial 
plot shows the reallocation flow for T stages and overall stages according to the modified TNM staging schema. 
Orange color indicates patients with strap muscle invasion  (T3bNanyM0) who were restaged according to tumor 
size. The number of patients in each T stage of the AJCC 8th TNM staging schema or the modified TNM staging 
schema are presented along the left and right margins.
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Statistical analysis. Statistical analyses were performed using commercially available software (R software, 
version 3.6.1 (https ://www.R-proje ct.org, R Foundation for Statistical Computing, Vienna, Austria) with the 
application of appropriate R packages (survival, survminer, cmprsk, compareC, ggplot2 and alluvial)24–29. The 
Cox proportional hazard analysis was used to examine the effects of clinical factors and histopathologic charac-
teristics of DTC on DSS. Competing risk analysis by proportional subdistribution hazards regression modeling 
was  performed26,30. In this study, competing risk was considered death due to other causes since deaths unrelated 
to DTC may obscure the ability to observe cancer-caused  deaths31. Kaplan–Meier estimation and the log rank 
test were used to assess 10-year DSS probability and DSS curves according to T stages based on either the AJCC 
8th TNM staging schema or the modified TNM staging schema. The measure of discrimination for survival pre-
diction was estimated using C-index, and goodness-of-fit for survival prediction was estimated using the PVE 
for both staging  schemas32. All tests were two-sided, and a p-value of less than 0.05 was considered statistically 
significant.
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